I-Flow/HAPC
This article was originally published in The Gray Sheet
Executive Summary
Proposed sale price of I-Flow's InfuSystem infusion pump distribution subsidiary is reduced from $140 million to $100 million, plus a $12 million "earn out payment," under a memorandum of intent with purchaser HAPC, the firms announce Sept. 12. The price cut "reflects the realities of today's economic environment and the marketplace," explains I-Flow CEO Donald Earhart. The planned divestiture was announced last September to allow I-Flow to focus on its On-Q pain drug-delivery devices (1"The Gray Sheet" Oct. 9, 2006, p. 11)
You may also be interested in...
I-Flow’s Focus Is On-Q As It Drops Infusion Pump Distribution Unit
I-Flow's divestiture of its infusion pump distribution subsidiary InfuSystem for $140 mil. will help fund clinical trials and market share expansion efforts for its On-Q infusion system, the firm says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.